In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

We use cookies to optimise the design of this website and make continuous improvement. By continuing your visit, you consent to the use of cookies. Learn more

Cell transplantation for myocardial regeneration

Cardiovascular Pharmacology and Pharmacotherapy

Cell transplantation for myocardial regeneration: the end of the beginning (maybe)

In this session, prestigious experts in the field provided a comprehensive update on the most critical aspects of stem cell therapy for cardiac regeneration and repair.

Prof. Bartunek, from Aalst, Belgium, discussed the potential of different somatic cells, highlighting the importance of paracrine factors to improve resident and transplanted cell performance and the promising role of the new family of guided cardiopoietic cells.

Prof. Anthony Marhur, from London, UK, comprehensively reviewed the different methods of cell delivery existing to date, emphasising the already well-established feasibility and safety of intracoronary delivery using a simple PCI-like approach and the percutaneous intramyocardial delivery through the NOGA system.

The lecture by Prof. Lipiecki, from Paris, France, focused on cell transplantation delivery during cardiac surgery, highlighting the safety of this approach and the promising results of bone marrow cells in this setting.

Finally, Prof. Andreas Zeiher, from Frankfurt, Germany, provided a critical overview of clinical trials. It seems to be clear that clinical application of stem cell therapies for cardiac repair is feasible and safe, with a benefit that depends on cell product, method of delivery and clinical setting. In patients with STEMI, early IC application has a favorable risk-benefit ratio and fulfils criteria for large-scale randomized clinical trials. In chronic patients, navigator-guided transendocardial delivery is feasible and safe. The quest for the “ideal” cell is still ongoing.

In summary, together with basic research, this innovation requires parallel translational investigation based on large animal models and phase 1-2 clinical trials to explore other scenarios and cells and to answer specific questions (cell processing, biological efficacy, dose, timing, associations, delivery and guiding, etc)




Cell transplantation for myocardial regeneration

Notes to editor

This congress report accompanies a presentation given at the ESC Congress 2009. Written by the author himself/herself, this report does not necessarily reflect the opinion of the European Society of Cardiology.

The content of this article reflects the personal opinion of the author/s and is not necessarily the official position of the European Society of Cardiology.